AGP Executive Report
Last update: 6 hours agoDiagnostic Stewardship: An infectious-disease doctor argues the US overuses tests like urine cultures, driving unnecessary antibiotics and worsening resistance. Medication Safety: Pharmacist guidance flags B12 deficiency risks tied to meds such as proton pump inhibitors and metformin, while separate warnings cover side effects for omeprazole and metformin users. Healthcare Costs & Policy: Texas businesses feel squeezed as healthcare costs rise and lawmakers look for solutions; Ohio economists are split on Medicaid fraud-prevention reforms. Cancer Access: India’s cancer burden prompts a Rajya Sabha panel to seek ideas on affordable screening, diagnosis, and care. Regulatory & Industry Moves: CMS proposes “site-neutral” imaging payment reforms to cut $260M in spending; IDMA says nutraceuticals should stay OTC to support preventive care. Public Health Alerts: NYC reports 14 Legionnaires’ disease cases on the Upper East Side, with officials urging symptom monitoring. Care Delivery & Tech: AIIMS Delhi used blockchain-enabled tools to fill 460+ faculty vacancies; CommonSpirit Health apologizes for radiology report delays after outsourcing reads. Hospital Expansion: Fortis Healthcare signs an O&M deal for a 300-bed hospital in Odisha; Magnet Hospitals launches in Bengaluru with plans for 12 locations.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Traditional Healthcare Has a Retention Problem It Refuses to Diagnose]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26438233-924731290-49c69f0716ecaf56987f7864d9c6ed65a343ac47-1280x720-100x56.jpeg)
![<![CDATA[Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26438663-924731352-6fa8f218cd866c4c9ab9499dd0c07d8443c05365-1920x1080-100x56.jpeg)
![<![CDATA[How Regulatory Stringency, Demand Shocks, and Repurposing Reshape Biopharma Strategy in 2026]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26438928-924731349-867db9d5f94684fd686652c8d92cfb8d565da866-5376x3584-100x67.jpeg)
